alanine has been researched along with Angina at Rest in 15 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| " The 2 populations studied were as follows: (1) a cross-sectional study of 703 acute coronary syndrome (ACS) patients with myocardial infarction (MI) and unstable angina, and (2) a prospective study of 924 Caucasian patients from the OPUS (Orbofiban in Patients with Unstable coronary Syndromes)-TIMI-16 trial of the oral GPIIb/IIIa antagonist orbofiban." | 5.10 | Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. ( Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC, 2002) |
| " Oral GP IIb/IIIa inhibitors have been associated with an increased incidence of bleeding, but additional experience may permit the design of dosing regimens that decrease this risk." | 1.31 | Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. ( Cannon, CP, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muckian, C | 1 |
| Fitzgerald, A | 2 |
| O'Neill, A | 1 |
| O'Byrne, A | 1 |
| Fitzgerald, DJ | 4 |
| Shields, DC | 2 |
| Cantor, WJ | 1 |
| Goodman, SG | 1 |
| Cannon, CP | 7 |
| Murphy, SA | 1 |
| Charlesworth, A | 2 |
| Braunwauld, E | 1 |
| Langer, A | 1 |
| Mager, DE | 1 |
| Shirey, JD | 1 |
| Cox, D | 2 |
| Abernethy, DR | 1 |
| Smith, EE | 1 |
| Murphy, S | 2 |
| Feske, SK | 1 |
| Schwamm, LH | 1 |
| Scirica, BM | 2 |
| Cooper, R | 1 |
| Aster, RH | 1 |
| Brassard, J | 1 |
| McCabe, CH | 3 |
| Skene, AM | 1 |
| Braunwald, E | 4 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Morrow, DA | 1 |
| de Lemos, JA | 1 |
| Sabatine, MS | 1 |
| Wiviott, SD | 1 |
| Rifai, N | 1 |
| Newby, LK | 1 |
| McGuire, DK | 1 |
| Bhatt, DL | 1 |
| Topol, EJ | 1 |
| Smith, R | 1 |
| Quinn, M | 1 |
| Theroux, P | 1 |
| Crean, P | 1 |
| Wilcox, RG | 1 |
| Bentley, JH | 1 |
| Anders, R | 1 |
| Kleiman, J | 1 |
| Nicholson, N | 1 |
| Wazowicz, B | 1 |
| Burns, D | 1 |
| O'Connor, FF | 1 |
| Tashchuk, VK | 1 |
| Shumakov, VA | 1 |
| Malinovskaia, IE | 1 |
3 reviews available for alanine and Angina at Rest
| Article | Year |
|---|---|
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trial | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mon | 2000 |
Xemilofiban/orbofiban: insight into drug development.
Topics: Alanine; Angina, Unstable; Animals; Benzamidines; Bleeding Time; Clinical Trials, Phase II as Topic; | 2001 |
8 trials available for alanine and Angina at Rest
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional S | 2002 |
Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Topics: Aged; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary A | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Diseas | 2007 |
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Platele | 2000 |
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.
Topics: Aged; Alanine; Angina, Unstable; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Ag | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
4 other studies available for alanine and Angina at Rest
| Article | Year |
|---|---|
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Topics: Alanine; Angina, Unstable; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; | 2005 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Topics: Alanine; Angina, Unstable; Benzamidines; Humans; Myocardial Infarction; Platelet Aggregation Inhibit | 2000 |
[Apex cardiography in the hemodynamic assessment of patients with unstable stenocardia].
Topics: Alanine; Angina Pectoris; Angina, Unstable; beta-Alanine; Cardiac Pacing, Artificial; Echocardiograp | 1989 |